Correlation of T Regulatory Cells, Cytotoxic T-lymphocyte-associated Antigen 4, and Transforming Growth Factor-β1 with Treatment Response in Patients with Chronic Myeloid Leukemia Receiving Dasatinib Therapy
Annals of African Medicine · 2025
DOI: 10.4103/aam.aam_5_24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of African Medicine, 2025. Verfasst von Akanksha Singh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, King George's Medical University, Lucknow, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Dasatinib, Transforming Growth Factor beta1, T-Lymphocytes, Regulatory, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Background
Tyrosine kinase inhibitors improve chronic myeloid leukemia (CML) outcomes. Dasatinib inhibits breakpoint cluster region-Abelson 1 proto-oncogene tyrosine kinase better than imatinib in CML. T-regulatory cells prevent autoimmune diseases and aberrant immune responses by reducing oncoprotein antigen reactivity. They also reduce self-antigen-induced immune responses to maintain peripheral tolerance. In this study, T-regulatory cells in peripheral blood of chronic myeloid leukemia-chronic phase patients were measured, together with serum levels of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and transforming growth factor (TGF)-β1 at diagnosis and 3 months postdasatinib therapy. Materials and Methods: The Pathology and Clinical Haematology Departments at King George’s Medical University, Lucknow, India, conducted this prospective analytical study. Forty CML-chronic patients and 10 healthy controls were analyzed. Flow cytometry was used to determine T-regulatory cell percentage in peripheral blood mononuclear cells of newly diagnosed CML patients before and after 3 months of dasatinib treatment; ELISA was used to measure serum levels of CTLA-4 and TGF-β1.
Results
T-regulatory cells, CTLA-4, and TGF-β1 significantly decreased in CML-chronic phase patients after 3 months of dasatinib therapy compared to the initial diagnosis. No significant change in T-regulatory cell, CTLA-4, or TGF-β1 percentages were seen between responders and poor responders. However, responders had a lower percentage of T-regulatory cells than suboptimal responders.
Conclusions
The study concluded that dasatinib treatment improved response in CML patients with decreased Treg cells. Dasatinib reduces Treg-mediated immunological suppression, reducing CTLA-4 and TGF-β1 levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, King George's Medical University, Lucknow, Uttar Pradesh, India.
- Department of Clinical Hematology, King George's Medical University, Lucknow, Uttar Pradesh, India.
Zitieren
APA
Singh, A., Singh, A., Kushwaha, R., Verma, S. P., Ali, W., & Singh, U. S. (2025). Correlation of T Regulatory Cells, Cytotoxic T-lymphocyte-associated Antigen 4, and Transforming Growth Factor-β1 with Treatment Response in Patients with Chronic Myeloid Leukemia Receiving Dasatinib Therapy. Annals of African Medicine. https://doi.org/10.4103/aam.aam_5_24
Vancouver
Singh A, Singh A, Kushwaha R, Verma SP, Ali W, Singh US. Correlation of T Regulatory Cells, Cytotoxic T-lymphocyte-associated Antigen 4, and Transforming Growth Factor-β1 with Treatment Response in Patients with Chronic Myeloid Leukemia Receiving Dasatinib Therapy. Annals of African Medicine. 2025. doi:10.4103/aam.aam_5_24
BibTeX
@article{Singh2025,
author = {Singh, Akanksha and Singh, Anurag and Kushwaha, Rashmi and Verma, Shailendra Prasad and Ali, Wahid and Singh, Uma Shankar},
title = {Correlation of T Regulatory Cells, Cytotoxic T-lymphocyte-associated Antigen 4, and Transforming Growth Factor-β1 with Treatment Response in Patients with Chronic Myeloid Leukemia Receiving Dasatinib Therapy},
journal = {Annals of African Medicine},
year = {2025},
doi = {10.4103/aam.aam_5_24}
}
EUVIMED